About BELLUS Health (TSE:BLU)
BELLUS Health Inc. is a drug development company focused on rare diseases. The business activities of the Company are development of the Company's core technology platform, amyloid inhibitors, which focus on chemical compounds that could have the potential to inhibit the formation, deposition and toxicity of amyloid fibrils, which are the underlying causes of certain diseases. The Company operates in the business segment of development of drugs for health solutions. It is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. Its pipeline of rare disease projects includes KIACTA in Phase III for Amyloid A (AA) amyloidosis; KIACTA for sarcoidosis; clinical stage Shigamab for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS), and a research-stage project for amyloid light-chain (AL) amyloidosis. It is partnered with global private equity firm Auven Therapeutics for the development of KIACTA.
Industry, Sector and Symbol:
- Sector: Basic Materials
- Industry: Industrial Metals & Minerals
- Sub-Industry: N/A
- Symbol: TSE:BLU
- CUSIP: N/A
- Web: www.bellushealth.com
- Market Cap: C$29.42 million
- Outstanding Shares: 66,865,000
- 50 Day Moving Avg: C$0.39
- 200 Day Moving Avg: C$0.37
- 52 Week Range: C$0.21 - C$0.55
Sales & Book Value:
- Trailing P/E Ratio: 110.00
- P/E Growth: 0.00
- Annual Revenue: $767,000.00
- Price / Sales: 38.36
- Book Value: C$0.16 per share
- Price / Book: 2.75
- Net Margins: 651.22%
- Return on Equity: 9.83%
- Return on Assets: 8.85%
- Average Volume: 60,997 shs.
- Short Ratio: 0.04
Frequently Asked Questions for BELLUS Health (TSE:BLU)
What is BELLUS Health's stock symbol?
BELLUS Health trades on the Tornton Stock Exchange (TSX) under the ticker symbol "BLU."
How were BELLUS Health's earnings last quarter?
BELLUS Health Inc (TSE:BLU) released its earnings results on Wednesday, August, 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.02). The business earned $0.42 million during the quarter, compared to the consensus estimate of $1 million. BELLUS Health had a return on equity of 9.83% and a net margin of 651.22%. View BELLUS Health's Earnings History.
When will BELLUS Health make its next earnings announcement?
Who are some of BELLUS Health's key competitors?
Some companies that are related to BELLUS Health include Canadian Zinc Corp. (CZN), Golden Queen Mining (GQM), Foraco International S.A. (FAR), Thompson Creek Metals Company (TC), Eastern Platinum (ELR), Verde Agritech PLC (NPK), West African Minerals Corporation (WAFM), Ferrum Crescent Limited (FCR), Ausdrill Limited (ASL), BHP Billiton Limited (BHP), Duketon Mining Ltd (DKM), Energy Resources of Australia Limited (ERA), Fortescue Metals Group Limited (FMG), Horsehead Holding Corp. (ZINC), Iluka Resources Limited (ILU), Maca Ltd (MLD), Mineral Deposits Limited (MDL) and Mineral Resources Limited (MIN).
How do I buy BELLUS Health stock?
Shares of BELLUS Health and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is BELLUS Health's stock price today?
MarketBeat Community Rating for BELLUS Health (TSE BLU)MarketBeat's community ratings are surveys of what our community members think about BELLUS Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of BELLUS Health stock can currently be purchased for approximately C$0.44.
Earnings History for BELLUS Health (TSE:BLU)Earnings History by Quarter for BELLUS Health (TSE BLU)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017|| || || || || || || || |
|8/13/2014||C($0.02)||C($0.02)||C$1.00 million||C$0.42 million||View||N/A|
Earnings Estimates for BELLUS Health (TSE:BLU)
Current Year EPS Consensus Estimate: $-0.03 EPS
Dividend History for BELLUS Health (TSE:BLU)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for BELLUS Health (TSE:BLU)Insider Trades by Quarter for BELLUS Health (TSE:BLU)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
Headline Trends for BELLUS Health (TSE:BLU)
Latest Headlines for BELLUS Health (TSE:BLU)
|BELLUS Health Inc (BLU) Director Pierre Larochelle Buys 275,000 Shares|
www.americanbankingnews.com - October 3 at 11:16 PM
|BELLUS Health Appoints Dr. Clarissa Desjardins to its Board of Directors|
finance.yahoo.com - October 2 at 12:59 PM
|BELLUS Health (BLUSF) Updates On BLU-5937 & Chronic Cough Key Opinion Leader Event - Slideshow|
seekingalpha.com - September 21 at 4:23 PM
|BELLUS Health Chronic Cough Webcast Taking Place Today|
finance.yahoo.com - September 20 at 5:22 PM
|BRIEF-Bellus Health's BLU-5937 reduces cough without taste disturbance in two preclinical models|
www.reuters.com - September 18 at 4:57 PM
|BELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models|
finance.yahoo.com - September 18 at 4:57 PM
|Report Coverage on Healthcare Stocks, BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics|
finance.yahoo.com - September 14 at 5:15 PM
|BELLUS Health to host webcast on chronic cough and treatment approach on September 20, 2017|
finance.yahoo.com - September 6 at 4:38 PM
|BELLUS Health, Inc. :BLU-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017|
finance.yahoo.com - August 15 at 5:27 PM
|BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2017|
finance.yahoo.com - August 9 at 4:48 PM
|Research Initiated on Healthcare Stocks, BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics|
finance.yahoo.com - August 7 at 5:08 PM
|BELLUS Health, Inc. :BLU-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 4, 2017|
finance.yahoo.com - August 4 at 9:57 PM
|BELLUS Health Inc (BLU) Set to Announce Quarterly Earnings on Tuesday|
www.americanbankingnews.com - August 1 at 7:31 AM
|Roberto Bellini Buys 225,000 Shares of BELLUS Health Inc (TSE:BLU) Stock|
www.americanbankingnews.com - July 18 at 4:18 PM
|BELLUS Health Inc. (BLU.TO)|
finance.yahoo.com - July 9 at 4:29 PM
|BELLUS Health announces closing of the sale of its equity interest in FB Health for total consideration up to CA$2.5M|
finance.yahoo.com - July 3 at 4:39 PM
|Active Wall Street: Research Reports Initiated on Healthcare Stocks BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics|
www.finanznachrichten.de - June 3 at 5:04 AM
|Bellus posts 1Q profit|
marketbeat.com - May 10 at 5:20 AM
|IIROC Trading Halt - BLU|
www.bizjournals.com - March 1 at 8:49 AM
|Canadian Stocks Are Rising As Brexit Looks Unlikely -- Canadian Commentary|
www.nasdaq.com - June 22 at 8:38 AM
|Savaria, Premium at 52-Week Highs|
www.baystreet.ca - May 5 at 1:43 PM
|Study Reached 120 Qualifying Events, Top-Line Results Expected in Q2 2016|
globenewswire.com - January 21 at 10:13 AM
BELLUS Health (BLU) Chart for Thursday, October, 19, 2017